Skip to main content

Table 5 Prevalence of use of different antihypertensive drug classes in patients with or without metabolic syndrome

From: Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy

  β-blockers ACEIs ARBs CCBs Diuretics α1 adrenergic blockers
No metabolic syndrome
 Whole population (n = 62) 23 (37.1) 18 (29.0) 27 (43.5) 11 (54.8) 32 (14.5) 2 (3.2)
 Only antihypertensive (n = 55) 21 (38.2) 15 (27.3) 26 (47.3) 9 (16.4) 29 (52.7) 1 (1.8)
 Antihypertensive plus antidiabetic or lidip lowering drugs (n = 7) 2 (28) 3 (42.9) 1 (14.3) 2 (28.6) 3 (42.9) 1 (1.8)
Metabolic syndrome
 Whole population (n = 67) 22 (32.8) 21 (31.3) 28 (41.8) 14 (40.3) 28 (22.4) 5 (7.5)
 Only antihypertensive (n = 49) 14 (28.6) 17 (34.7) 19 (38.8) 11 (22.4) 20 (40.8) 3 (6.1)
 Antihypertensive plus antidiabetic or lidip lowering drugs (n = 18) 8 (44.4) 4 (22.2) 9 (50.0) 3 (16.7) 8 (44.4) 2 (11.1)
  1. The numbers in parentheses represent the percentage of the total of the respective group